Home Newsfeeds Chardan Capital Downgrades Vascular Biogenics to Neutral

Chardan Capital Downgrades Vascular Biogenics to Neutral

Chardan Capital analyst Matthew Barcus downgrades Vascular Biogenics (NASDAQ:VBLT) from Buy to Neutral.

byBenzinga Newsdesk

July 21, 2022

1 minute read

Chardan Capital analyst Matthew Barcus downgrades Vascular Biogenics (NASDAQ:VBLT) from Buy to Neutral.

General
News

American Eagle’s Quiet Platforms Expands Fulfillment Capacity

By Shivani Kumaresan

July 20, 11:23 AM

American Eagle Outfitters Inc (NYSE:AEO) subsidiary Quiet Platforms has expanded its fulfillment capacity by activating a new, multifunctional, connected fulfillment facility…

AEO

Goldman Sachs Maintains Buy on Morgan Stanley, Raises Price Target to $94

By Benzinga Newsdesk

September 21, 8:37 AM

Goldman Sachs analyst Richard Ramsden maintains Morgan Stanley (NYSE:MS) with a Buy and raises the price target from $85 to $94.

What’s In The World Is Going On With Multi Ways Holdings (MWG) Stock Falling 60%

By Henry Khederian

April 28, 1:43 PM

Multi Ways Holdings Ltd (NASDAQ: MWG) shares are trading lower by some Friday afternoon. The stock is falling on heavy volume as of 12:40pm EDT despite a lack of company-specific news. So What's Up?

MWG

Elon Musk Hurls Fraud Allegations At Twitter With Whistleblower’s Claims Amid Legal Wrangle

By Ramakrishnan M

September 16, 12:58 AM

Tesla Inc (NASDAQ: TSLA) CEO Elon Musk has thrown more serious allegations at Twitter Inc (NYSE: TWTR), potentially dragging a legal battle between the two parties over the billio

TSLA

Chardan Capital Downgrades Vascular Biogenics to Neutral

Related Posts

American Eagle’s Quiet Platforms Expands Fulfillment Capacity

Goldman Sachs Maintains Buy on Morgan Stanley, Raises Price Target to $94

What’s In The World Is Going On With Multi Ways Holdings (MWG) Stock Falling 60%

Elon Musk Hurls Fraud Allegations At Twitter With Whistleblower’s Claims Amid Legal Wrangle